NuMedii
NuMedii is a next-generation biopharma company that leverages Big Data and Artificial Intelligence (AI) to accelerate the discovery of precision therapies. Their proprietary AIDD (Artificial Intelligence for Drug Discovery) technology integrates vast amounts of genomic, molecular, and biomedical data with AI and machine learning algorithms to identify connections between drugs and diseases at a systems level. This approach moves beyond traditional target-centric drug discovery by exploring 'poly-pharmacology' to potentially improve therapeutic efficacy by modulating multiple disease pathways. NuMedii partners with global pharmaceutical and biotech companies, as well as patient-centric organizations, to discover novel drugs, targets, and biomarkers for various therapeutic areas, including inflammation, oncology, and rare diseases. They also build their own pipeline in rare inflammatory diseases and rare oncology indications.
NuMedii
NuMedii is a next-generation biopharma company that leverages Big Data and Artificial Intelligence (AI) to accelerate the discovery of precision therapies. Their proprietary AIDD (Artificial Intelligence for Drug Discovery) technology integrates vast amounts of genomic, molecular, and biomedical data with AI and machine learning algorithms to identify connections between drugs and diseases at a systems level. This approach moves beyond traditional target-centric drug discovery by exploring 'poly-pharmacology' to potentially improve therapeutic efficacy by modulating multiple disease pathways. NuMedii partners with global pharmaceutical and biotech companies, as well as patient-centric organizations, to discover novel drugs, targets, and biomarkers for various therapeutic areas, including inflammation, oncology, and rare diseases. They also build their own pipeline in rare inflammatory diseases and rare oncology indications.
TL;DR
What: Next‑generation biopharma using Big Data + AI to accelerate precision drug discovery
Core technology: AIDD (Artificial Intelligence for Drug Discovery) platform integrating genomic/molecular/biomedical data with ML and network algorithms
Founded: 2008
Funding (disclosed): $5.5M across disclosed rounds (2013 $3.5M; 2015 $2.0M)
Therapeutic focus: Inflammation, oncology, rare diseases